4//SEC Filing
venBio Global Strategic Fund II L.P. 4
Accession 0001012975-20-000113
CIK 0001744659other
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 4:06 PM ET
Size
14.2 KB
Accession
0001012975-20-000113
Insider Transaction Report
Form 4
venBio Global Strategic Fund II L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-02-04$25.65/sh−53,731$1,378,179→ 3,268,407 total(indirect: See footnote) - Sale
Common Stock
2020-02-05$25.99/sh−28,608$743,548→ 3,239,799 total(indirect: See footnote)
venBio Global Strategic GP II, L.P.
10% Owner
Transactions
- Sale
Common Stock
2020-02-04$25.65/sh−53,731$1,378,179→ 3,268,407 total(indirect: See footnote) - Sale
Common Stock
2020-02-05$25.99/sh−28,608$743,548→ 3,239,799 total(indirect: See footnote)
venBio Global Strategic GP II, Ltd.
10% Owner
Transactions
- Sale
Common Stock
2020-02-04$25.65/sh−53,731$1,378,179→ 3,268,407 total(indirect: See footnote) - Sale
Common Stock
2020-02-05$25.99/sh−28,608$743,548→ 3,239,799 total(indirect: See footnote)
Adelman Robert J
10% Owner
Transactions
- Sale
Common Stock
2020-02-04$25.65/sh−53,731$1,378,179→ 3,268,407 total(indirect: See footnote) - Sale
Common Stock
2020-02-05$25.99/sh−28,608$743,548→ 3,239,799 total(indirect: See footnote)
GOODMAN COREY S
10% Owner
Transactions
- Sale
Common Stock
2020-02-04$25.65/sh−53,731$1,378,179→ 3,268,407 total(indirect: See footnote) - Sale
Common Stock
2020-02-05$25.99/sh−28,608$743,548→ 3,239,799 total(indirect: See footnote)
Footnotes (3)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.96, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.20 to $26.27, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
- [F3]These shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, LP is the sole general partner of venBio Global Strategic Fund II, LP and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Robert Adelman and Corey Goodman are directors of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Mr. Adelman and Mr. Goodman disclaims beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein.
Documents
Issuer
Akero Therapeutics, Inc.
CIK 0001744659
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001634632
Filing Metadata
- Form type
- 4
- Filed
- Feb 5, 7:00 PM ET
- Accepted
- Feb 6, 4:06 PM ET
- Size
- 14.2 KB